(alt="")
 (alt="")

What happens
after screening?

What comes next?

  • In most cases, results will be available within a few weeks

  • Depending on how you accessed screening, your results may be accessible to you directly or through your healthcare team
 (alt="")

What do the results mean?

 (alt="")

0 autoantibodies:

If no autoantibodies are detected, autoimmune T1D has not been detected.1,2 Repeat screening may be recommended for children at higher risk of developing the condition.2

 (alt="")

1 autoantibody:

If one autoantibody is detected, it means there is a higher risk of developing autoimmune T1D.2 Monitoring and additional repeat screening may be recommended to see if there are any changes.2

(alt="")

2+ autoantibodies:

If two or more different autoantibodies are detected and the result is confirmed, then autoimmune T1D has been detected.2 Further testing of blood sugar levels may be recommended to understand how the condition is progressing.2

What if I’m still unsure?

If you have any questions about screening or what comes next, your healthcare team will be available to support you.


Regardless of the results, autoantibody screening for autoimmune T1D is not about creating worry, it’s about preparation – giving you and your family valuable knowledge and time to plan for life with the condition.4–6

 (alt="")

Understandably, learning you or a loved one has, or is more likely to develop autoimmune T1D may cause anxiety, but your healthcare team will support you and your family with the next steps.2,3

Download Doctor Discussion Guide

References

  1. Sims EK, Besser REJ, Dayan C, et al. Diabetes. 2022;71(4):610-623.

  1. Phillip M, Achenbach P, Addala A, et al. Diabetes Care. 2024;47(8):1276-1298.

  1. Moore DJ, Leibel NI, Polonsky W, et al. Int J Gen Med. 2024;17:3003-3014.

  1. Quinn LM, Rashid R, Narendran P, et al. Br J Gen Pract. 2023;73(726):36-39.

  1. Quinn LM, Dias RP, Greenfield SM, et al. Diabet Med. 2024:e15490.

  1. Besser REJ, Bell KJ, Couper JJ, et al. Pediatr Diabetes. 2022;23(8):1175-1187.


MAT-GLB-2503978-v1.0-07/2025